The primary component of Forsythia suspense, forsythin, is therapeutically used to treat fever, viral colds, gonorrhoea, and ulcers. The objective of this study was to assess the safety of forsythin for human use as well as any potential genetic harm. The Ames test, chromosomal aberration (CA) test, and bone marrow micronucleus (MN) test were used to evaluate the genetic toxicity of forsythin in vivo in accordance with GLP standards and test guidelines. In the Ames test, the number of His + revertant colonies was counted after five Salmonella typhimurium strains were subjected to varying forsythin concentrations in the presence or absence of the S9 mixture. In the CA test, chromosomal abnormalities were identified after treating Chinese hamster lung (CHL) fibroblast cells with various concentrations of forsythin, mitomycin C, or cyclophosphamide in the presence or absence of the S9 mixture. The MN test involved isolating the bone marrow from the mice that had received various treatments and calculating the ratios of polychromatic erythrocytes (PCE) and erythrocytes (PCE/(PCE + NCE)). Following the division of the beagle dogs into four groups-a negative control group, a lowdose group, a medium-dose group, and a high-dose group-a telemetry system was utilised to assess the safety of forsythin use. Results from the Ames test revealed that whether the S9 was present or not, there was no statistically dose-dependent increase in the number of colonies in any of the test strains.